Veracyte
No price chart data available for 1D timeframe.
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Geno...
Latest News
4 days ago · seekingalpha.com
Veracyte: Solid Profits, Slowing Tests, And A Stock In LimboVeracyte is rated Hold, as its valuation premium has vanished, but growth prospects have weakened, especially for Decipher prostate cancer testing. Decipher's test volume growth is slowing sharply, with management now planning for a 40% lower annual increase versus prior years. VCYT trades at 2.87x forward sales and 12.95x earnings, below sector medians, yet consensus expects a 19.38% EPS decline in 2027.
6 days ago · seekingalpha.com
Veracyte, Inc. (VCYT) Presents at 2026 UBS Global Healthcare Conference TranscriptVeracyte, Inc. ( VCYT ) 2026 UBS Global Healthcare Conference November 10, 2026 4:15 PM EST Company Participants Marc Stapley - CEO & Director Rebecca Chambers - Executive VP & CFO Conference Call Participants Douglas Schenkel - UBS Investment Bank, Research Division Presentation Douglas Schenkel UBS Investment Bank, Research Division All right. Good afternoon.
11 days ago · zacks.com
Veracyte Q3 Earnings Call Highlights Slower Growth and Added InvestmentVCYT beats Q3 earnings estimates but trims its 2026 revenue outlook as Decipher growth slows and investments in breast and bladder cancer testing rise.
11 days ago · prnewswire.com
VCYT SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Veracyte/PRNewswire/ -- A $100 million buyback authorization and $151.8 million in third-quarter revenue did not hold up Veracyte, Inc. (NASDAQ: VCYT) shares, which
11 days ago · seekingalpha.com
Veracyte, Inc. (VCYT) Q3 2026 Earnings Call TranscriptVeracyte, Inc. ( VCYT ) Q3 2026 Earnings Call November 5, 2026 4:30 PM EST Company Participants Kelly Gura - Director of Investor Relations Marc Stapley - CEO & Director Rebecca Chambers - Executive VP & CFO John Leite - Global Chief Commercial Officer Conference Call Participants Puneet Souda - Leerink Partners LLC, Research Division Douglas Schenkel Lauren Timmins - Jefferies LLC, Research Division Mason Carrico - Stephens Inc., Research Division Kyle Mikson - Canaccord Genuity Corp., Research Division Michael Matson - Needham & Company, LLC, Research Division Keith Hinton - Prime Executions, Inc., Research Division Presentation Operator Good day, and thank you for standing by. Welcome to the Veracyte Third Quarter 2026 Financial Results Conference Call.
12 days ago · marketbeat.com
What Veracyte (VCYT) Said on Its Q3 Earnings CallVeracyte NASDAQ: VCYT reported 15% revenue growth for the third quarter of 2026, but lowered its near-term expectations for its Decipher Prostate test after volume came in below management's forecast. The company also outlined a preliminary 2027 outlook for mid-single-digit revenue growth as it invests in its commercial teams and expands its cancer testing portfolio.
12 days ago · zacks.com
Veracyte (VCYT) Tops Q3 Earnings and Revenue EstimatesVeracyte (VCYT) came out with quarterly earnings of $0.51 per share, beating the Zacks Consensus Estimate of $0.44 per share. This compares to earnings of $0.51 per share a year ago.
18 days ago · globenewswire.com
Veracyte to Participate in Upcoming Investor ConferencesSOUTH SAN FRANCISCO, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced it will be participating in the following investor conferences: UBS Global Healthcare Conference – Palm Beach Gardens, FLFireside chat on Tuesday, November 10 at 4:15 p.m.
20 days ago · zacks.com
Veracyte (VCYT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?Veracyte (VCYT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
25 days ago · globenewswire.com
Phase III Trial Shows Veracyte's Decipher Prostate Test Can Predict Benefit from Adding Abiraterone to Treatment in Very High-Risk Prostate CancerSTAMPEDE study analysis providing new predictive evidence in clinically very high-risk, nonmetastatic disease to be presented at ESMO STAMPEDE study analysis providing new predictive evidence in clinically very high-risk, nonmetastatic disease to be presented at ESMO
Earnings
Analyst Summary
Add to Watchlist
Select watchlists to add or remove VCYT